| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4548 | 2018 |
| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 3235 | 2019 |
| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2480 | 2019 |
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009 | 2426 | 2009 |
| Renal cell carcinoma BI Rini, SC Campbell, B Escudier The Lancet 373 (9669), 1119-1132, 2009 | 2296 | 2009 |
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial BI Rini, B Escudier, P Tomczak, A Kaprin, C Szczylik, TE Hutson, ... The Lancet 378 (9807), 1931-1939, 2011 | 2233 | 2011 |
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal … RJ Motzer, MD Michaelson, BG Redman, GR Hudes, G Wilding, RA Figlin, ... Journal of Clinical Oncology 24 (1), 16-24, 2006 | 2174 | 2006 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1969 | 2020 |
| Sunitinib in patients with metastatic renal cell carcinoma RJ Motzer, BI Rini, RM Bukowski, BD Curti, DJ George, GR Hudes, ... Jama 295 (21), 2516-2524, 2006 | 1645 | 2006 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1352 | 2015 |
| Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial RJ Motzer, BI Rini, DF McDermott, BG Redman, TM Kuzel, MR Harrison, ... Journal of clinical oncology 33 (13), 1430-1437, 2015 | 1222 | 2015 |
| Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ... Journal of Clinical Oncology 26 (33), 5422-5428, 2008 | 1202 | 2008 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1161 | 2018 |
| External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ... The lancet oncology 14 (2), 141-148, 2013 | 1148 | 2013 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1125 | 2016 |
| Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ... Journal of clinical oncology 28 (13), 2137-2143, 2010 | 1035 | 2010 |
| Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3 … BI Rini, T Powles, MB Atkins, B Escudier, DF McDermott, C Suarez, ... The Lancet 393 (10189), 2404-2415, 2019 | 1007 | 2019 |
| Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients JS Ko, AH Zea, BI Rini, JL Ireland, P Elson, P Cohen, A Golshayan, ... Clinical cancer research 15 (6), 2148-2157, 2009 | 1000 | 2009 |
| Combination immunotherapy with prostatic acid phosphatase pulsed antigen‐presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer … BI Rini, V Weinberg, L Fong, S Conry, RM Hershberg, EJ Small Cancer: Interdisciplinary International Journal of the American Cancer …, 2006 | 914 | 2006 |
| Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial RJ Motzer, B Escudier, P Tomczak, TE Hutson, MD Michaelson, S Negrier, ... The Lancet Oncology 14 (6), 552-562, 2013 | 898 | 2013 |
Toni ChoueiriDana-Farber Cancer InstitutePotvrđena adresa e-pošte na dfci.harvard.edu
